Alector (ALEC) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palisade Bio (PALI) has outperformed Alector (ALEC) over the past year, losing 11.9% versus a loss of 37.5%. Over five years, ALEC leads with a -91.8% price change compared with -99.9% for PALI. Palisade Bio is the larger company by market cap ($243.1 million vs $220.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | PALI |
|---|---|---|
| Share price | $1.98 | $1.40 |
| Market cap | $220.52M | $243.11M |
| 1-day change | +2.86% | -5.74% |
| YTD return | +23.08% | -37.02% |
| 1-year return | -37.46% | -11.90% |
| 5-year return | -91.76% | -99.93% |
| P/E ratio (TTM) | — | 2.32 |
| EPS (TTM) | $-1.09 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $2.86 |
| 52-week low | $1.09 | $1.32 |
| Distance from 52-week high | -41.91% | -51.22% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +67.09% | +632.62% |
| Average volume | 2.77M | 2.60M |
| Shares outstanding | 111.66M | 174.27M |
| Employees | 103 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed ALEC by 25.6 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
ALEC vs PALI FAQ
Which is bigger, Alector or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $243.11M compared with $220.52M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or PALI?
PALI returned -11.90% over the past 12 months, compared with -37.46% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.